KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitBusiness Wire • 12/12/24
Lost Money on Kyverna Therapeutics, Inc.(KYTX)? Join Class Action Suit Seeking Recovery – Contact Levi & KorsinskyAccesswire • 12/12/24
Kyverna Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Investors With Losses Are Invited To Reach Out To The Schall Law FirmAccesswire • 12/12/24
The Law Offices of Frank R. Cruz Announces Investigation of Kyverna Therapeutics, Inc. (KYTX) on Behalf of InvestorsBusiness Wire • 12/12/24
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Kyverna Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KYTXGlobeNewsWire • 12/11/24
KYTX INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Kyverna Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead the Kyverna Class Action LawsuitGlobeNewsWire • 12/11/24
KYTX Investors Have Opportunity to Lead Kyverna Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmPRNewsWire • 12/11/24
KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 12/11/24
KYVERNA THERAPEUTICS SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Kyverna Therapeutics, Inc. - KYTXBusiness Wire • 12/11/24
Kyverna Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. February 7, 2025 Deadline to file Lead Plaintiff Motion.GlobeNewsWire • 12/10/24
Rosen Law Firm Urges Kyverna Therapeutics, Inc. (NASDAQ: KYTX) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their RightsBusiness Wire • 12/10/24
Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Kyverna Therapeutics, Inc.PRNewsWire • 12/10/24
KYVERNA THERAPEUTICS, INC. (NASDAQ: KYTX) INVESTOR ALERT: Investors With Large Losses in Kyverna Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their RightsGlobeNewsWire • 12/10/24
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Kyverna Therapeutics, Inc. (KYTX)GlobeNewsWire • 12/10/24
KYTX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Kyverna Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!Accesswire • 12/10/24
SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Kyverna Therapeutics, Inc. (KYTX) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the FirmGlobeNewsWire • 12/10/24
Kyverna Therapeutics Sued for Securities Fraud; Investors Should Contact Block & Leviton to Learn How They Might Recover LossesAccesswire • 12/10/24
Kyverna Therapeutics, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities LawsuitGlobeNewsWire • 12/09/24
Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Kyverna Therapeutics, Inc. (NASDAQ: KYTX)Business Wire • 12/09/24
Kyverna Therapeutics Announces New Patient Data Highlighting Potential of KYV-101 for Treatment of Lupus Nephritis in Symposium at ACR Convergence 2024PRNewsWire • 11/14/24
Kyverna Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial ResultsPRNewsWire • 11/13/24
Kyverna Therapeutics Presents Patient Data Reinforcing Potential of KYV-101 for Treatment of Neuroinflammatory Diseases in Symposium at ECTRIMS 2024PRNewsWire • 09/18/24
Kyverna Therapeutics, Inc. May Have Committed Securities Fraud And The Schall Law Firm Encourages Shareholders To Join An InquiryAccesswire • 09/11/24